Skip to main content

Pipeline

Moberg Pharma has developed a pipeline of late stage drug candidates with a combined sales potential estimated at 350–700 MUSD. MOB-015 is our next generation

nail fungus treatment and BUPI is our novel oral pain relief associated with inflammation and ulceration of the oral mucous membranes (oral mucositis or OM), a serious complication following cancer treatment. Both drug candidates are in Phase 3 and have demonstrated strong Phase 2 results, indicating that they have the potential to become market leaders in their respective niches. The estimated sales potential is USD 250–500 million for MOB-015 and USD 100–200 million for BUPI.